Literature DB >> 32229549

Management of difficult-to-treat Clostridioides difficile in a patient with chronic osteomyelitis.

Mikaela Highland Sullivan1, Victoria Lynn Boggiano2, Kelly Lacy Smith1.   

Abstract

A 61-year-old male patient being treated with intravenous antibiotics for left foot osteomyelitis presented to the hospital septic, with several days of worsening abdominal pain, bloating and watery bowel movements. Investigation revealed that the patient had severe, treatment-resistant Clostridioides difficile colitis. He was initially treated with oral vancomycin and intravenous metronidazole, which was switched to oral fidaxomicin. After no improvement in the patient's symptoms, he was treated with two faecal microbiota transplants. He was offered a third faecal microbiota transplant but declined. The patient was placed back on oral fidaxomicin and saw ultimate resolution of his symptoms. This case provides an example of a treatment pathway for refractory C. difficile infection. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastroenterology; hepatitis and other gastrointestinal infection; infection (gastroenterology); infectious diseases

Mesh:

Substances:

Year:  2020        PMID: 32229549      PMCID: PMC7167421          DOI: 10.1136/bcr-2019-233095

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  21 in total

1.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

Review 2.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

3.  The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010.

Authors:  Kelly R Reveles; Grace C Lee; Natalie K Boyd; Christopher R Frei
Journal:  Am J Infect Control       Date:  2014-10       Impact factor: 2.918

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

6.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

Review 7.  Clostridium difficile Colitis Prevention and Treatment.

Authors:  Meltem Dinleyici; Yvan Vandenplas
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 8.  Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.

Authors:  M N Quraishi; M Widlak; N Bhala; D Moore; M Price; N Sharma; T H Iqbal
Journal:  Aliment Pharmacol Ther       Date:  2017-07-14       Impact factor: 8.171

Review 9.  Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.

Authors:  Saeed S Banawas
Journal:  Biomed Res Int       Date:  2018-02-21       Impact factor: 3.411

10.  Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.

Authors:  Wenjia Hui; Ting Li; Weidong Liu; Chunyan Zhou; Feng Gao
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.